Xin Lang Cai Jing·2025-08-25 10:31Group 1 - The core viewpoint of the article is that Fosun Pharma is launching a new A+H share equity incentive plan, focusing on net profit attributable to shareholders and revenue from innovative drugs as key performance indicators [1] - The incentive plan is seen as a significant indicator of Fosun Pharma's future development, highlighting its focus on innovative drugs and management's confidence in the company's growth prospects [1] - Innovation is identified as the core engine for Fosun Pharma's sustained growth, with the company enriching its innovative product pipeline through various collaboration models [1] Group 2 - Fosun Pharma has established three major R&D platforms, focusing on antibody and ADC, small molecules, and cell therapy, while also investing in cutting-edge technologies [1] - The company has achieved significant international business development results since 2025, including licensing agreements for biosimilars in multiple countries [1] - Fosun Pharma's net profit attributable to shareholders is projected to increase from 2.77 billion yuan in 2024 to 4.77 billion yuan by 2027, representing a growth of 72.2% [1]